Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials

Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials

Abstract Background PARP inhibitors (PARPi) have a well-established role in platinum-sensitive ovarian cancer (PSOC), in BRCA mutant (BRCAm), and homologous recombination deficiency (HRD) population. However, their role in wild type and homologous recombination proficient population is still not cle...

Full description

Bibliographic Details
Main Authors: Roli Purwar, Rakesh Ranjan, Manjusha Pal, Satyanshu K. Upadhyay, Tarun Kumar, Manoj Pandey
Format: Article
Language:English
Published: BMC 2023-05-01
Series:World Journal of Surgical Oncology
Online Access:https://doi.org/10.1186/s12957-023-03027-4

Internet

https://doi.org/10.1186/s12957-023-03027-4

Similar Items